SAGE Therapeutics (SAGE) Tops Q4 EPS by 36c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sage Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline and Business Progress
February 27, 2020 6:30 AM ESTZULRESSO (brexanolone) CIV injection net revenues of $2M and $4M for fourth quarter and full year 2019, respectively
Evaluating path forward for the zuranolone (SAGE-217) Landscape Program
Continued expansion of Neurology and Neuropsychiatry franchises with planned initiation of additional SAGE-324 and SAGE-718 studies in 2020
Conference call today at 8:00 a.m. EST
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of... More
